1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,260 | 0,274 | 12:01 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.09. | Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry | 229 | PR Newswire | Viva Biotech is acknowledged for its pioneering AI-driven drug discovery platforms that accelerate timelines, reduce costs, and expand therapeutic innovation in the global pharmaceutical... ► Artikel lesen | |
| 29.09. | Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry | 298 | PR Newswire | Viva Biotech is acknowledged for its pioneering AI-driven drug discovery platforms that accelerate timelines, reduce costs, and expand therapeutic innovation in the global pharmaceutical... ► Artikel lesen | |
| 25.09. | VIVA BIOTECH (01873): INTERIM REPORT 2025 | - | HKEx | ||
| 02.09. | Unlocking the Potential of Cyclic Peptide Therapeutics: Viva Biotech's Discovery Insights | 223 | PR Newswire | SHANGHAI, Sept. 2, 2025 /PRNewswire/ -- Peptides have recently emerged at the forefront of therapeutic innovation, with cyclic peptides gaining particular attention for their ability to bridge... ► Artikel lesen | |
| 28.08. | Viva Biotech Announces Its 2025 Interim Results: CRO Revenue Returned to Positive Growth, New CDMO Commercialization Projects Showed Promising Growth | 329 | PR Newswire | Financial Highlights for Interim Results ended 30 June 2025Revenue reached RMB831.9 millionGross profit amounted to RMB339.4 millionGross profit margin was 40.8%, an increase of 6.3 percentage... ► Artikel lesen | |
| 28.08. | VIVA BIOTECH (01873): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025 | 2 | HKEx | ||
| 18.08. | VIVA BIOTECH (01873): DATE OF BOARD MEETING | 2 | HKEx | ||
| VIVA BIOTECH Aktie jetzt für 0€ handeln | |||||
| 12.06. | VIVA BIOTECH (01873): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 12, 2025 | 2 | HKEx | ||
| 04.06. | VIVA BIOTECH (01873): SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO CONNECTED TRANSACTION | - | HKEx | ||
| 30.05. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 28.05. | VIVA BIOTECH (01873): CONNECTED TRANSACTION INVESTMENT IN LIMITED PARTNERSHIP FUND | 1 | HKEx | ||
| 15.05. | Viva Biotech Launches the AI-Driven Drug Discovery Platform, Transforming New Drug R&D Logic, Enabling One-Stop Innovative Drug Discovery | 337 | PR Newswire | SHANGHAI, May 15, 2025 /PRNewswire/ -- On May 13, 2025, Viva Biotech successfully held the AIDD platform launch event "Enchantment of Drug Discovery," unveiling the advanced and comprehensive... ► Artikel lesen | |
| 28.03. | Viva Biotech's Wholly-Owned Subsidiary Langhua Pharmaceutical Successfully Passes U.S. FDA On-Site Inspection | 364 | PR Newswire | SHANGHAI, March 28, 2025 /PRNewswire/ -- Zhejiang Langhua Pharmaceutical Co., Ltd. ("Langhua Pharmaceutical"), a wholly-owned subsidiary of Viva Biotech Holdings... ► Artikel lesen | |
| 27.03. | Viva Biotech Announces 2024 Annual Results: Significantly Rebounding in Performance with New Stage ahead, AI Leads to a New Era of Novel Drug R&D | 175 | PR Newswire | Highlights of Annual Results for the Year Ended December 31, 2024 Revenue reached RMB1,986.7 million Gross profit amounted to RMB687.4 million Net profit recorded... ► Artikel lesen | |
| 11.12.24 | Viva Biotech Officially Establishes Boston Branch, Marking Another Milestone in Global Expansion | 412 | PR Newswire | HONG KONG, Dec. 11, 2024 /PRNewswire/ -- Recently, Viva Biotech Holdings Group ("Viva Biotech") announced the official establishment of its new branch in Boston, USA. As a global leader in... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 3,956 | -1,59 % | Valneva-Aktie rückt zum Wochenstart in den Mittelpunkt - Marktteilnehmer bleiben wachsam! | ||
| NOVONESIS | 52,26 | +0,77 % | AKTIEN IM FOKUS: Chemiewerte unter Druck - Analystin befürchtet langen Abschwung | FRANKFURT (dpa-AFX) - Ein skeptischer Branchenkommentar der Deutschen Bank hat am Mittwoch bei Chemiewerten Spuren hinterlassen. Allen voran galt dies für die Aktien von Lanxess, die wegen einer gestrichenen... ► Artikel lesen | |
| GENMAB | 247,60 | -0,08 % | H.C. Wainwright Maintains a Buy Rating on Genmab A/S (GMAB) | ||
| ARBUTUS BIOPHARMA | 4,182 | +1,16 % | Arbutus Biopharma Corporation: Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran Dr. Roger Sawhney joins the Arbutus Board of Directors following resignation... ► Artikel lesen | |
| BEONE MEDICINES LTD ADR | 268,00 | -0,74 % | BeOne Medicines Ltd.: BeOne Medicines to Present at Upcoming Investor Conferences | BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in fireside chats at two upcoming investor conferences:
Guggenheim... ► Artikel lesen | |
| SINO BIOPHARM | 0,776 | +2,75 % | Aktienmarkt: Aktie von Sino Biopharmaceutical tritt auf der Stelle (0,88 €) | Wenig Kursbewegung zur Stunde bei der Sino Biopharmaceutical-Aktie . Das Wertpapier notiert aktuell bei 0,88 Euro. Ein geringes Minus von 5,12 Prozent zeigt die Kurstafel für die Aktie von Sino Biopharmaceutical... ► Artikel lesen | |
| VERICEL | 30,200 | -0,66 % | Vericel Corporation: Vericel Reports Second Quarter 2025 Financial Results | Total Revenue Growth of 20% to $63.2 Million, with MACI Revenue Growth of 21% to $53.5 Million Gross Margin Increased More than 400 Basis Points to 74% Adjusted EBITDA Growth of 112% to $13.4 Million... ► Artikel lesen | |
| MOLECULIN BIOTECH | 0,510 | -100,00 % | Moleculin Biotech, Inc.: Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin | HOUSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 9,570 | 0,00 % | Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value | BOSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,400 | +1,78 % | MustGrow Biologics Corp.: MustGrow Announces Grant of RSUs and DSUs | Saskatoon, Saskatchewan--(Newsfile Corp. - September 26, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") today announced that the board of directors... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 1,742 | +0,11 % | BioXcel Therapeutics, Inc. - 8-K, Current Report | ||
| ZAI LAB LTD ADR | 23,600 | +3,51 % | Zai Lab Limited: Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025 | -Data highlights potential of ZL-1503 as a promising treatment for moderate-to-severe atopic dermatitis and other IL-13 and IL-31-driven diseases -Favorable preclinical safety profile, prolonged... ► Artikel lesen | |
| REGENXBIO | 11,200 | +0,90 % | Exosomen statt Viren: Warum NurExone, Regenxbio und Voyager den Markt für Nerventherapien verändern könnten | ||
| CSTONE PHARMACEUTICALS | 0,680 | -2,86 % | CSTONE PHARMA-B (02616): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION | ||
| AKEBIA | 1,894 | -0,94 % | Morning Market Movers: Cambium Networks, Stride, Inc., Varonis Systems, Akebia Therapeutics See Big Swings | CANBERA (dpa-AFX) - At 7:25 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen |
Das Unternehmen VIVA BIOTECH HOLDINGS kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,260 Euro und damit -0,76 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIVA BIOTECH HOLDINGS finden Sie auf Wallstreet Online.